Posts Tagged ‘atrial fibrillation’

Stroke and Bleeding in Afib with CKD

Posted by Sara Fazio • August 17th, 2012

In a study of data from Danish national registries, CKD was associated with an increased risk of stroke and bleeding among patients with atrial fibrillation. Warfarin decreased the risk of stroke among such patients. Both warfarin and aspirin increased the risk of bleeding. The prevalence of both atrial fibrillation and chronic kidney disease increases with age…. Read More…

Subclinical Atrial Fibrillation

Posted by Sara Fazio • January 13th, 2012

In a study from Healey et al, a cohort of 2580 patients with pacemakers or defibrillators were monitored for 3 months to detect subclinical atrial tachyarrhythmias. Patients with subclinical atrial tachyarrhythmias had a significantly increased risk of subsequent ischemic stroke. Atrial fibrillation may be asymptomatic and consequently subclinical. Epide­miologic studies indicate that many patients with atrial fibrillation… Read More…

Catheter Ablation for Atrial Fibrillation

Posted by Sara Fazio • December 16th, 2011

The latest article in our Clinical Therapeutics series begins with a 59-year-old man who presents with a recurrent episode of symptomatic atrial fibrillation despite attempts to maintain sinus rhythm with antiarrhythmic drugs. Catheter ablation can be effective in such patients, but more than one procedure may be necessary. Atrial fibrillation affects up to 5 million… Read More…

Another choice for combatting clot? Apixaban for patients with atrial fibrillation

Posted by Lisa Rosenbaum • September 14th, 2011

To get some protection against stroke in atrial fibrillation, we, along with our patients have been living with the hassles of warfarin, because we have to. But warfarin may not be our only choice for much longer. In this week’s NEJM, the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)… Read More…

Rivaroxaban for Atrial Fibrillation

Posted by Graham McMahon • September 9th, 2011

In the ROCKET-AF trial, 14,264 patients with atrial fibrillation were randomly assigned to receive either rivaroxaban or warfarin. In a perprotocol, as-treated analysis, rivaroxaban was noninferior to warfarin with respect to the primary end point of stroke or systemic embolism.     The use of vitamin K antagonists is highly effective for stroke prevention in patients with nonvalvular… Read More…